ArticleJournal of neuro-oncology2013
Prognostic significance of CD147 in patients with glioblastoma.
Article in Journal of neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 7 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Glioblastoma invasion patterns from a clinical perspective-a systematic review.Neurosurgical review · 2024Pooled it
- CD147 and glioma: a meta-analysis.Journal of neuro-oncology · 2017Pooled it
- Elevated CD147 expression is associated with shorter overall survival in non-small cell lung cancer.Oncotarget · 2017Pooled it
- CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis.BioMed research international · 2017Pooled it
- CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis.Scientific reports · 2016Pooled it
- Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.Oncotarget · 2015Pooled it
- Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis.BioMed research international · 2015Pooled it
- EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival.BioMed research international · 2014Trial
- Spatial and single-cell dissection of medulloblastoma identifies developmental hierarchies and a prognostic PPIA-BSG tumor-immune axis.Journal of translational medicine · 2026Article
- Basigin (CD147) and calpain 4 (CapnS1) are partners in the generation of traction force but not in mechanosensing.The Journal of biological chemistry · 2026Article
- CAR-T cell therapy for the treatment of adult high-grade gliomas.NPJ precision oncology · 2024Review
- The Roles of GDF-9, BMP-15, BMP-4 and EMMPRIN in Folliculogenesis and In Vitro Fertilization.Journal of clinical medicine · 2024Review
- The Role of Antibody-Based Therapies in Neuro-Oncology.Antibodies (Basel, Switzerland) · 2023Review
- Optimizing CAR-T Therapy for Glioblastoma.Molecular diagnosis & therapy · 2023Review
- Advanced T and Natural Killer Cell Therapy for Glioblastoma.Journal of Korean Neurosurgical Society · 2023Article
- Review
- CD147: an integral and potential molecule to abrogate hallmarks of cancer.Frontiers in oncology · 2023Review
- CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.Frontiers in immunology · 2022Review
- Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations.Frontiers in immunology · 2022Review
- Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD147, also known as extracellular matrix metalloproteinase inducer, is a widely distributed cell surface glycoprotein that belongs to the immunoglobulin superfamily. CD147 has been proved to be enriched on the surface of many tumor cells, promoting tumor growth, invasion and metastasis by its stimulation effect on adjacent fibroblasts to produce matrix metalloproteinases. In this study, we aimed to explore the expression pattern of CD147 in glioblastoma (GBM) and investigate whether it could be used to assess subsequent prognosis of patients. For that, we recruited a total of 206 patients with pathologically confirmed GBM and 36 normal control brain tissue specimens. The expression of CD147 in GBM and normal tissues was investigated by immunohistochemistry assay. Genetic factors including MGMT and IDH1 mutation were also investigated to justify the prognostic significance of CD147. Results showed that CD147 expression was increased in GBM compared with that in normal tissues. Kaplan-Meier analysis showed that increased CD147 expression was associated with poor overall survival of patients with GBM. Moreover, Cox's proportional hazards model revealed that CD147 expression was an independent and significant prognostic marker of overall survival in GBM patients. These results proved that CD147 expression was relatively abundant in GBM and can be potentially used to predict prognosis and treatment response in GBM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.